UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

Benzinga · 1d ago
UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.